{"id":723,"date":"2026-09-01T15:21:54","date_gmt":"2026-09-01T15:21:54","guid":{"rendered":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/"},"modified":"2026-09-01T15:32:23","modified_gmt":"2026-09-01T15:32:23","slug":"tirzepatida-em-1-2539-adultos-durante-72-semanas","status":"publish","type":"case_study","link":"https:\/\/nhdbio.com\/pt-br\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","title":{"rendered":"Tirzepatide SURMOUNT-1: 2,539 Adultos ao longo de 72 semanas"},"content":{"rendered":"<h2>Por que SURMOUNT-1 \u00e9 um estudo \u00e2ncora \u00fatil<\/h2>\n<p>SURMOUNT-1 \u00e9 um grande estudo randomizado de Fase 3 com um grupo de placebo e desfechos coprim\u00e1rios pr\u00e9-especificados. Portanto, apoia uma discuss\u00e3o de evid\u00eancias cl\u00ednicas mais forte do que alega\u00e7\u00f5es mecanicistas ou observa\u00e7\u00f5es n\u00e3o controladas. O artigo tamb\u00e9m relata o conjunto completo de grupos de doses randomizados, em vez de um n\u00famero escolhido seletivamente.<\/p>\n<h2>Popula\u00e7\u00e3o e endpoints<\/h2>\n<p>O ensaio incluiu adultos com BMI de pelo menos 30, ou pelo menos 27 com complica\u00e7\u00e3o relacionada ao peso, e excluiu diabetes. Os participantes foram randomizados igualmente para tr\u00eas grupos de tirzepatida ou placebo. O regime de tratamento estimou e avaliou os resultados independentemente da descontinua\u00e7\u00e3o do tratamento na popula\u00e7\u00e3o com inten\u00e7\u00e3o de tratar.<\/p>\n<h2>Resultados no contexto<\/h2>\n<p>Todos os tr\u00eas grupos de tirzepatida diferiram do placebo nos par\u00e2metros de peso relatados. O artigo tamb\u00e9m relata eventos adversos gastrointestinais como os mais comuns, geralmente durante a escalada, e fornece porcentagens de descontinua\u00e7\u00e3o para cada grupo randomizado. Manter vis\u00edveis esses denominadores e dados de eventos adversos impede um resumo apenas da efic\u00e1cia.<\/p>\n<div class=\"pfm-case-callout\"><strong>Limite de compara\u00e7\u00e3o:<\/strong> SURMOUNT-1 n\u00e3o foi um teste retatrutide e n\u00e3o pode fornecer uma classifica\u00e7\u00e3o direta Retatrutide versus Tirzepatide. As porcentagens de testes cruzados v\u00eam de diferentes protocolos e est\u00e1gios de desenvolvimento.<\/div>\n<h2>Distin\u00e7\u00e3o de medicamento acabado<\/h2>\n<p>Os resultados cl\u00ednicos de um medicamento acabado revisado pelo regulador n\u00e3o podem ser transferidos para material que compartilhe um nome, mas que n\u00e3o possua a mesma formula\u00e7\u00e3o, sistema de entrega, especifica\u00e7\u00f5es de libera\u00e7\u00e3o e controles de qualidade. Esta distin\u00e7\u00e3o faz parte do registro de evid\u00eancias, e n\u00e3o uma nota de rodap\u00e9.<\/p>","protected":false},"excerpt":{"rendered":"<p>Uma leitura estruturada do ensaio SURMOUNT-1 Fase 3, preservando o desenho randomizado, resultados de quatro grupos, dados de descontinua\u00e7\u00e3o e a distin\u00e7\u00e3o entre um medicamento acabado aprovado e material para uso em pesquisa.<\/p>","protected":false},"author":0,"featured_media":851,"template":"","class_list":["post-723","case_study","type-case_study","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tirzepatide SURMOUNT-1 Trial: 2,539 Adults<\/title>\n<meta name=\"description\" content=\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/pt-br\/estudos-de-caso\/tirzepatida-em-1-2539-adultos-durante-72-semanas\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks\" \/>\n<meta property=\"og:description\" content=\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/pt-br\/estudos-de-caso\/tirzepatida-em-1-2539-adultos-durante-72-semanas\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T15:32:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\",\"name\":\"Tirzepatide SURMOUNT-1 Trial: 2,539 Adults\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"datePublished\":\"2026-09-01T15:21:54+00:00\",\"dateModified\":\"2026-09-01T15:32:23+00:00\",\"description\":\"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/tirzepatide-surmount-1-editorial-v2.webp\",\"width\":1672,\"height\":941,\"caption\":\"Editorial research illustration; not a photograph of trial participants or an actual study site.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/tirzepatide-surmount-1-2539-adults-72-weeks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6848\u4f8b\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Teste Tirzepatide SURMOUNT-1: 2,539 Adultos","description":"Uma leitura estruturada do ensaio SURMOUNT-1 Fase 3, preservando o desenho randomizado, resultados de quatro grupos, dados de descontinua\u00e7\u00e3o e a distin\u00e7\u00e3o entre um medicamento acabado aprovado e material para uso em pesquisa.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/pt-br\/estudos-de-caso\/tirzepatida-em-1-2539-adultos-durante-72-semanas\/","og_locale":"pt_BR","og_type":"article","og_title":"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks","og_description":"A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and research-use material.","og_url":"https:\/\/nhdbio.com\/pt-br\/estudos-de-caso\/tirzepatida-em-1-2539-adultos-durante-72-semanas\/","og_site_name":"NHD","article_modified_time":"2026-09-01T15:32:23+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","url":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/","name":"Teste Tirzepatide SURMOUNT-1: 2,539 Adultos","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","datePublished":"2026-09-01T15:21:54+00:00","dateModified":"2026-09-01T15:32:23+00:00","description":"Uma leitura estruturada do ensaio SURMOUNT-1 Fase 3, preservando o desenho randomizado, resultados de quatro grupos, dados de descontinua\u00e7\u00e3o e a distin\u00e7\u00e3o entre um medicamento acabado aprovado e material para uso em pesquisa.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/tirzepatide-surmount-1-editorial-v2.webp","width":1672,"height":941,"caption":"Editorial research illustration; not a photograph of trial participants or an actual study site."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/case-studies\/tirzepatide-surmount-1-2539-adults-72-weeks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"\u6848\u4f8b","item":"https:\/\/nhdbio.com\/case-studies\/"},{"@type":"ListItem","position":3,"name":"Tirzepatide SURMOUNT-1: 2,539 Adults Over 72 Weeks"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mat\u00e9rias-primas pept\u00eddicas e s\u00edntese personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/case_study\/723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/case_study\/723\/revisions"}],"predecessor-version":[{"id":728,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/case_study\/723\/revisions\/728"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media\/851"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media?parent=723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}